Furthermore, conventional therapies do not adequately target the underlying pathophysiological mechanisms of Type 2 Diabetes Mellitus (T2DM), particularly insulin resistance and β-cell dysfunction, leading to the progressive deterioration of β-cell function and subsequent disease progression. The gene discussed is INS; the disease is type 2 diabetes mellitus.